Edition:
India

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

291.87USD
16 Feb 2018
Change (% chg)

$-7.51 (-2.51%)
Prev Close
$299.38
Open
$297.75
Day's High
$298.50
Day's Low
$290.98
Volume
1,201,826
Avg. Vol
509,441
52-wk High
$370.53
52-wk Low
$244.31

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $69,239.67
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

Norway to buy Biogen's Spinraza medicine: broadcaster NRK

OSLO Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc at a cost of 7 million Norwegian crowns ($880,381.33) per year per patient, public broadcaster NRK reported on Monday.

12 Feb 2018

Norway to buy Biogen's Spinraza medicine -broadcaster NRK

OSLO, Feb 12 Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc at a cost of 7 million Norwegian crowns ($880,381.33) per year per patient, public broadcaster NRK reported on Monday.

12 Feb 2018

Biogen stops testing Tysabri to treat stroke after study fails

Biogen Inc will stop testing established drug Tysabri for the treatment of acute ischemic stroke after it failed a mid-stage study, the U.S. drugmaker said on Wednesday.

07 Feb 2018

UPDATE 2-Biogen stops testing Tysabri to treat stroke after study fails

Feb 7 Biogen Inc will stop testing established drug Tysabri for the treatment of acute ischemic stroke after it failed a mid-stage study, the U.S. drugmaker said on Wednesday.

07 Feb 2018

BRIEF-Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke

* BIOGEN REPORTS TOP-LINE RESULTS FROM PHASE 2B STUDY OF NATALIZUMAB IN ACUTE ISCHEMIC STROKE

07 Feb 2018

Biogen stops developing Tysabri to treat stroke after failed study

Feb 7 Biogen Inc said on Wednesday it would stop developing Tysabri to treat acute ischemic stroke patients after the drug failed to meet the main goal of a mid-stage study.

07 Feb 2018

BRIEF-Biogen Reports Top-Line Results From Phase 2B Study Of Natalizumab

* BIOGEN REPORTS TOP-LINE RESULTS FROM PHASE 2B STUDY OF NATALIZUMAB IN ACUTE ISCHEMIC STROKE

07 Feb 2018

UPDATE 3-Biogen forecasts robust 2018 as Spinraza sales surge

* Sees 2018 revenue of $12.7 bln-$13 bln vs $12.7 bln (Adds background on Spinraza and deals)

25 Jan 2018

Biogen forecasts robust 2018, quarterly revenue beats on Spinraza sales

U.S. drugmaker Biogen Inc on Thursday reported fourth-quarter revenue that beat Wall Street estimates on higher sales for its drug Spinraza and forecast an upbeat 2018, sending its shares up 3 percent in premarket trading.

25 Jan 2018

Biogen posts fourth-quarter loss on income tax charge

Jan 25 U.S. drugmaker Biogen Inc reported a quarterly loss compared with a year-ago profit on Thursday due to a hefty income tax charge for recent changes to the U.S. tax code.

25 Jan 2018

Competitors

Earnings vs. Estimates